All In Biotech

NDA 050795 · Mayne Pharma

Doryx Mpc

Doxycycline Hyclate · Oral

Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

May 6, 2005

Approved uses

5

Original approval plus efficacy supplements

Registered trials

424

81 Phase 3, 42 recruiting

FAERS reports

17,469

10,251 serious, 2,363 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 16, 2026.

DORYX MPC is a tetracycline class drug indicated for: Rickettsial Infections ( 1.1 ) Sexually Transmitted Infections ( 1.2 ) Respiratory Tract Infections( 1.3 ) Specific Bacterial Infections ( 1.4 ) Ophthalmic Infections ( 1.5 ) Anthrax, Including Inhalational Anthrax (Post-Exposure) ( 1.6 ) Alternative Treatment for Selected Infections when Penicillin is Contraindicated ( 1.7 ) Adjunctive Therapy in Acute Intestinal Amebiasis and Severe Acne ( 1.8 ) Prophylaxis of Malaria ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, DORYX MPC Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Rickettsial Infections DORYX MPC is indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . 1.2 Sexually Transmitted Infections DORYX MPC is indicated for treatment of the following sexually transmitted infections: Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum . Lymphogranuloma venereum caused by Chlamydia trachomatis . Granuloma inguinale caused by Klebsiella granulomatis . Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Chancroid caused by Haemophilus ducreyi . 1.3 Respiratory Tract Infections DORYX MPC is indicated for treatment of the following respiratory tract infections: Respiratory tract infections caused by Mycoplasma pneumoniae . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Because many strains of the following groups of microorganisms have been shown to be...

Mechanism: Doxycycline is a tetracycline-class antimicrobial drug [ see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

8 products under this application
  • DORYX MPC · DOXYCYCLINE HYCLATE EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued
  • DORYX · DOXYCYCLINE HYCLATE EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • DORYX · DOXYCYCLINE HYCLATE EQ 80MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • DORYX · DOXYCYCLINE HYCLATE EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • DORYX MPC · DOXYCYCLINE HYCLATE EQ 60MG BASE · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
  • DORYX · DOXYCYCLINE HYCLATE EQ 200MG BASE · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • DORYX · DOXYCYCLINE HYCLATE EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB
  • DORYX · DOXYCYCLINE HYCLATE EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, DELAYED RELEASE, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxycycline Hyclate" as an intervention, any sponsor and status, largest first.

All 424 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity2,304
  • fatigue1,817
  • nausea1,715
  • pain1,489
  • rash1,463
  • off label use1,432
  • drug ineffective1,415
  • headache1,402
  • diarrhoea1,371
  • dyspnoea1,349
  • vomiting1,339
  • pruritus1,166

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200514
200623
200725
200836
200988
2010107
2011142
2012255
2013251
2014341
2015561
20161,058
20171,008
20181,397
20191,669
20201,510
20211,127
20221,187
20231,262
20241,875
20252,125
20261,392

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Doryx Mpc (Doxycycline Hyclate)

2024 spending

$244K

Beneficiaries

141

244 claims

Per beneficiary

$1,729

$19.26 per unit

View as table
YearSpending
2020$64,227
2021$43,583
2022$37,447
2023$145,512
2024$243,799

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 59 on PubMed

Sponsor: Mayne Pharma · Also marketed as Doryx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.